Floatz Rating
C37/100
Confidence
Indicative
Sponsor
Mirati Therapeutics Inc.
Modality
UNKNOWN
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
22Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04975256CT.gov Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14) | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Malignant Colon Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| bi 1701963 (this asset) | Mirati Therapeutics Inc. | P1 | C · 37 |
| Tranexamic Acid | Assaf-Harofeh Medical Center | P4 | B |
| Oxaliplatin | Second Affiliated Hospital, School of Medicine, Zhejiang University | P2 | B |
| Fluorouracilum | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | P2 | B |
| Regorafenib | City of Hope Medical Center | P2 | B |
| Nivolumab | M.D. Anderson Cancer Center | P1/2 | B |
| Cetuximab | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | P2 | B |
| Irinotecan | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | P2 | B |
| Celecoxib | Tel-Aviv Sourasky Medical Center | P3 | CCC |
+26 more in the Malignant Colon Neoplasm cohort
Other indications for bi 1701963
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lung Cancer | — | P1 | C · 37 |
| Colorectal Cancer | — | P1 | C · 37 |
| Cancer | — | P1 | C · 35 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. bi 1701963 in Malignant Colon Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 15, 2026. https://terminal.floatz.ai/assets/bi-1701963-malignant-colon-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →